Qiagen N.v.

HILDEN, Germany and GAITHERSBURG, Maryland, November 2, 2011 - - Vaginal Self-collection for Hybrid Capture-based HPV Testing Increases Screening Coverage and is More Sensitive than Pap Smear Shows a Mexican Study Published Today Online in the Lancet Promising findings published today online in the Lancet[1] from a community-based, randomized equivalence trial undertaken by public health authorities in Mexico to investigate DNA home testing for human papillomavirus (HPV) compared with cytology (evaluation of cells) based on Pap smears.

VENLO, The Netherlands, October 7, 2011 - QIAGEN N.V.

GERMANTOWN, Maryland and HILDEN, Germany, August 5, 2011 - Food and Drug Administration will reviewtherascreenKRAS RGQ PCR Kit for use with Erbitux(cetuximab), a metastatic colorectal cancer therapy PMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancer QIAGEN achieves milestones in Personalized Healthcare with innovative companion diagnostics; FDA decisions expected in 2012 QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has completed its second U.S.

VENLO, the Netherlands, June 15, 2011 - QIAGEN in exclusive negotiations to purchase 47% initial stake in Ipsogen S.A.and then fully acquire a global leader in hematologic (blood) cancer molecular diagnostics Ipsogen has a competitive portfolio in blood cancer testing with assays covering 15 biomarkers-including BCR-ABL and JAK2 -for patient profiling and monitoring Many of Ipsogen's assays have significant potential as companion diagnostics to help select and guide treatment decisions in personalized healthcare Addition of Ipsogen would strengthen QIAGEN's leadership in molecular diagnostics, significantly expanding its profiling and personalized healthcare portfolios QIAGEN N.V.

HILDEN, Germany and GERMANTOWN, Maryland, May 8, 2011 - QIAGEN N.V.